OAKVILLE, ON, March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately.
Mr. Craig Mull is the managing director of 1207407 Ontario Limited and is responsible for overseeing a variety of investments including the company's shareholding in Cipher. Mr. Mull is also the founder and CEO of the Typhon Group Ltd., a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area.
Mr. Mull has extensive experience in the Canadian healthcare industry, including holding the position of COO with CML HealthCare where he was responsible for the day-to-day operations. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from a market cap of $100 million to over $1.2 billion.
Mr. Mull also played an integral role in planning and structuring Cipher's initial public offering as it was spun out of CML.
"We are pleased to welcome Craig to the Cipher Board of Directors," said Mark Beaudet, Chair of Cipher's Board of Directors. "Craig has known Cipher since its initial public offering and adds transaction experience to Cipher's Board of Directors."
Mr. Craig Mull commented: "I'm excited to join the Board at this important stage in the Company's evolution. I look forward to assisting the team, as we continue to identify growth opportunities that enhance shareholder value."
About Cipher Pharmaceuticals Inc.
Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: Stefan Eftychiou, email@example.com, (905) 326-1888 ext. 60